Currently, Mirum Pharmaceuticals Inc [MIRM] is trading at $48.98, up 4.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MIRM shares have gain 8.15% over the last week, with a monthly amount glided 10.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on April 17, 2024, and set its price target to $48. On December 18, 2023, H.C. Wainwright reiterated its Buy rating and revised its price target to $58 on the stock. Morgan Stanley initiated its recommendation with a Overweight and recommended $60 as its price target on November 13, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $50.
This stock has fluctuated between a low of $24.53 and a high of $54.23 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $57.25 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $48.98 at the most recent close of the market. An investor can expect a potential return of 16.88% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Trailing Twelve Months sales for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] were 379.25M which represents 61.20% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.34 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] is 3.22. As well, the Quick Ratio is 3.04, while the Cash Ratio is 1.66. Considering the valuation of this stock, the price to sales ratio is 6.40, the price to book ratio is 10.38.
Transactions by insiders
Recent insider trading involved Ramasastry Saira, Director, that happened on Jun 02 ’25 when 5703.0 shares were sold. Director, Ramasastry Saira completed a deal on Jun 03 ’25 to sell 2500.0 shares. Meanwhile, Director SAIRA RAMASASTRY bought 2500.0 shares on Jun 03 ’25.
